AAAAAA

   
Results: 1-3 |
Results: 3
Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D-2 function
Authors: Alonso, R Voutsinos, B Fournier, M Labie, C Steinberg, R Souilhac, J Le Fur, G Soubrie, P
Citation: R. Alonso et al., Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D-2 function, NEUROSCIENC, 91(2), 1999, pp. 607-620
SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I: In vitro studies
Authors: Bignon, E Bachy, A Boigegrain, R Brodin, R Cottineau, M Gully, D Herbert, JM Keane, P Labie, C Molimard, JC Olliero, D Oury-Donat, F Petereau, C Prabonnaud, V Rockstroh, MP Schaeffer, P Servant, O Thurneyssen, O Soubrie, P Pascal, M Maffrand, JP Le Fur, G
Citation: E. Bignon et al., SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I: In vitro studies, J PHARM EXP, 289(2), 1999, pp. 742-751
Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex
Authors: Labie, C Lafon, C Marmouget, C Saubusse, P Fournier, J Keane, PE Le Fur, G Soubrie, P
Citation: C. Labie et al., Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, BR J PHARM, 127(1), 1999, pp. 139-144
Risultati: 1-3 |